Summary
This study is for people who have previously taken part in a Replimune clinical trial and received at least one dose of an RPx treatment.
The purpose of this study is to monitor participants' health over a longer period to identify any side effects that may develop after treatment has finished. No study treatment will be given as part of this follow-up study.
Participants will be followed for up to 5 years after joining the study. During this time, the study team will check for any new health issues that may be related to the RPx treatment, including:
- new cancers
- new or worsening nerve and brain conditions
- new or worsening autoimmune conditions
- blood disorders
- infections that may be related to the RPx treatment, including herpes-like infections.
If a participant develops a suspected herpes-like infection, they may be asked to provide a swab from the affected area. They may also be asked to provide additional samples, such as blood or urine, to help researchers understand whether the RPx treatment is present.
Participants will be contacted every 3 months for 5 years. Follow-up appointments may take place in person, by phone, by video call, or using another approved technology.
Taking part in this study helps researchers better understand the long-term safety of RPx treatments.